Beverly G. Tchang, MD (@BevTchangMD) header
Beverly G. Tchang, MD (@BevTchangMD) profile picture

#Endocrinologist. Passionate about #obesity as a medical disease and a social misunderstanding. Tweets are my own. | #health #medtwitter #weightloss #medicine |

New York, NY
Joined June 2017
Photo by Beverly G. Tchang, MD (@BevTchangMD)Photo by Beverly G. Tchang, MD (@BevTchangMD)Photo by Beverly G. Tchang, MD (@BevTchangMD)Photo by Beverly G. Tchang, MD (@BevTchangMD)Photo by Beverly G. Tchang, MD (@BevTchangMD)Photo by Beverly G. Tchang, MD (@BevTchangMD)Photo by Beverly G. Tchang, MD (@BevTchangMD)Photo by Beverly G. Tchang, MD (@BevTchangMD)Photo by Beverly G. Tchang, MD (@BevTchangMD)Photo by Beverly G. Tchang, MD (@BevTchangMD)
I'm trying something new with Muse AI and had it make a "space" page. If you're at @ObesityWeek, which #GLP1 pipelines are you watching? Here are the presentations I'll be following: 1. cagrisema 2. safiglipron 3. retatrutide 4. semaglutide 5. tirzepatide 6. cagrilintide and bone loss 7. eloralintide + tirzepatide 8. berobenatide 9. tirzepatide + mibavademab Check out the space to see how I think they will fit into the greater landscape of #obesity care 👉 muse.ai/s/glp-1-pipeline-at-… #OW2026 #ObesityWeek2026 @ObesitySociety
10
5
22
2,058
I have yet to validate this for accuracy! @Jmortonmd , did you say, "Bariatric surgery was GLP-1 before GLP-1 was cool" at yesterday's TOS/ASMBS session? 🙃 #OW2026
Congrats to my good friend, @BevTchangMD, on being named TOS Clinician of the Year! I’ll brag on her for a bit, too. She found a great conference hack: leveraging her Muse to attend virtual sessions she wanted to hear but couldn’t make in person, then having it watch and take notes for her. I followed her lead and was able to ingest roughly 3x more educational content and share those insights with my colleagues. Fantastic #OW2026 hack!
1
1
5
660
I am absolutely honored and humbled to receive the 2026 TOS Clinician of the Year Award. I truly believe every clinician could be deserving of this honor. As clinicians, patient care is core to our values, motivations, and actions, which is why we all go above and beyond our medical training to do more than just our "job." - Advocacy: How many times have you filled out prior authorizations, appeals, and done peer-to-peers? - Education: How many times have you discussed information from the Internet/AI and helped the patient understand whether or not it was applicable to them? Information is not education until you bring it back to the patient. - Research: How many times has a patient asked you about a side effect or effect, not known to be related to your intervention? Research starts and ends with patient experiences. I am grateful for The @ObesitySociety that has served as my second professional home and appreciate the gracious words from Yael Mauer, MD, MPH, FACP, DABOM, DACD and @cabandup Peminda Cabandugama MD DABOM FTOS . Thank you to everyone who has supported me throughout my career thus far including @OMFellowships and @ABOMcert @Ro , and in particular, ⭐️Alpana Shukla, MD, MRCP(UK), FTOS @alpanashuklamd who has always served as my compass--both professional and personally--and ⭐️@ljaronne Louis Aronne who had once encouraged me to "get in trouble" and still stands by me today when I do. I could not have a better work-family than I do at @WeillCornell Medicine Comprehensive Weight Control Center. #obesity #medicine #obesityweek2026 #OW2026
5
3
1
52
1,719
Beverly G. Tchang, MD retweeted
✅️ Newly presented LEAP trial at #ObesityWeek: 2 year trial of phentermine. 💊 What phentermine's impact on weight loss, hypertension, cardiovascular safety over a 2 year trial? ⚖️ Weight change at 1 and 2 years: Phentermine -8.2% at 1 year, -6.2% at 2 years Placebo -4.6% at 1 year, -4.7% at 2 years 🩺 No difference in blood pressure, serious or cardiac adverse events, hear rate +3 bpm. 🙌 It's refreshing seeing a NIH sponsored study demonstrate that there is a role for obesity medications in addition to the GLP-1 medicines.
8
13
41
2,397
I am wholeheartedly loving this Key Lecture delivered by @mbuman at @ObesityWeek on "Wearables as Engines of Metabolic Change" The framing of the problem is helpful--and something I point to all the time with my patients--particularly around data overload (separating signal from noise), and lack of hard endpoint data 👉 But remember that we struggle with some of these issues with our usual behavior interventions and studies: cross-sectional, single intervention, or short-term #ObesityWeek26 #OW2026 1/
2
2
1
16
1,363
4/ This relationship is precisely why I work in #academia and advise in #industry #telehealth #pharmaceuticals. Being able to leverage the strengths of both worlds to address each others' limits has been both fulfilling and fun.
1
1
1
122
Great point from Q&A Wearables have become so "passive" that we are no longer receiving that biofeedback and are losing the necessary reflection that is typically required to stimulate behavior change Are we losing some value of the intervention because the wearables have replaced active self-monitoring? More to come! @mbuman Please share this paper when it is published! 5/5
1
1
2
102
Beverly G. Tchang, MD retweeted
In one of the first ObesityWeek related data release, CagriSema demonstrates ~21% average weight loss on lower doses in the REDEFINE 9 trial. This demonstrates clinically transformative degrees of weight loss can be achieved with even less than half the maximum dose. CagriSema 1.0/1.0 mg produced 20.7% weight loss at 68 weeks. novonordisk.com/content/nnco…
3
6
19
2,219
Beverly G. Tchang, MD retweeted
Pleased to share our #OW2026 oral abstract’s full paper in @eClinicalMed. Our study could inform patient-clinician discussions about alternative therapy options in patients who consider switching or stopping semaglutide or tirzepatide. thelancet.com/action/showPdf…
3
9
20
1,440
I was recently asked, Q: Have the reports of NAION (nonarteritic anterior ischemic optic neuropathy) changed your practice habits with regards to Wegovy and Zepbound? 👉 fda.gov/drugs/drug-safety-co… A: Not really. But that's because I have been following the data closely (teapawt.org/bevtchangmd/status/197…) and already adjusted my practice. 🔹I counsel that NAION has multiple risk factors--diabetes, sleep apnea, daily tadalafil use--and we address what we can. 🔹For more data, patients can ask their ophthalmologist to measure their optic cup to disc ratio (ie, "disk at risk") See @MichaelAlbertMD's figure below 🔹The ultimate decision to start or continue a patient on #GLP1 in spite of NAION, is still a benefit>risk decision and... 🔹"The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society (NANOS) are advising patients to not panic. The warning is new, but our guidance is unchanged: NAION is rare, any added risk appears small, and it has not been established that these medications cause NAION." aao.org/newsroom/news-releas…
8
5
34
2,806
Important nuance here! Preserves SOME lean mass (which includes muscle and organ) by attenuating the reduction in lean mass
Replying to @BevTchangMD
@BevTchangMD -Studies of HAVE NOT shown that Resistance Training “PRESERVES” lean mass but may “ATTENUATE” the reduction (about 1 kg in this study). -Lean mass IS NOT all muscle mass. -The AI generated Infographic should not be applied to everyone - some are inappropriate.
1
6
1,122
ICYMI: #GLP1 has been linked to lower colorectal #cancer rates in adults with #obesity: journals.lww.com/ajg/abstrac… Presented at @AmCollegeGastro 2026, a retrospective observational study of 1.34 million people with obesity, GLP-1s over 6 months were linked to 67.5% lower colorectal cancer risk overall (risk ratio [RR], 0.33; 95% CI, 0.32-0.33; P <.0001) — 75% lower with tirzepatide and 56% lower with semaglutide. For adults age <45 years: a 71% reduction in rectal cancer risk (RR, 0.29; 95% CI, 0.21-0.38; P <.0001) Those are impressive confidence intervals! Here's a nice plain language summary: gastroenterologyadvisor.com/…
2
5
603
Resistance training attenuates lean mass loss on tirzepatide: 👉 lnkd.in/eiwh5Rr8 It's a bit of a "doh" moment but this is the first study to actually prove that strength training mitigates lean mass loss during medication-induced weight loss: We have been telling people to strength train, assuming it will preserve lean mass, based on prior studies of lifestyle/bariatric surgery intervention for obesity. So now we have real evidence to show that our advice applies to medication-induced weight loss too.  As a clinician, I care most about how to easily implement this in clinical practice. I had AI generate these infographics based on the trial protocol and my interpretation, with the second version more patient-friendly and using only bodyweight exercises so you don't need access to gym equipment. What do exercise physiologists think? @ReneeJRogers @jmjakicic 💎 My one liner to patients now is: "3 days a week of strength training, and you want to keep challenging yourself with more reps or higher weights as you progress through the year" #obesity #GLP1 #health #exercise #letsgetphysical
🤖 Made with AI
13
19
60
2,462
Someone really believes in berobenatide pfizer.com/news/press-releas…
1
1
10
1,847
I've worked with (and declined to work with) several #healthcare #healthtech startups in my career. What set @ZReitano and @Ro apart from them was (1) Personal experience and (2) Scientific curiosity. As a doctor close to academics and research, I prioritize evidence-based patient care. It surprised me to find a founder--who are typically "business"-first--who shared the same priority. I was taken by Z's personal origin story and his desire to remain close to proven therapies. Today, I am genuinely impressed by Ro's R&D, designed to meet patients where they are and to find out where the science can go next. To understand that level of commitment, you should check out the sheer number of abstracts we have had accepted at national scientific conferences. For example, upcoming obesityweek.org/ I'm grateful to have been part of their journey from early on and am proud seeing their vision come to life.
1
3
19
1,204